

UNIVERSITY MEDICAL CENTER
OF SOUTHERN NEVADA



REQUEST FOR INFORMATION

RFI NO.: 2011-20
Molecular Testing Equipment

UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA

REQUEST FOR INFORMATION

RFI No. 2011-20

Molecular Testing Equipment

UMC is looking to identify various suppliers that can provide Molecular Testing Equipment.

The RFI package is available as follows:

- a. Pick up - University Medical Center, Trauma Center, 800 Rose Street, Suite 408, Las Vegas, Nevada 89106.
- b. By Electronic Mail or Mail – Please email a request to Contracts Management at robert.maher@umcsn.com specifying project number and description. Be sure to include company address, phone and fax numbers, email address or call (702) 207-8846.
- c. Internet – Visit the Clark County website at www.clarkcountynv.gov/purchasing. Click on “Current Opportunities”, scroll to bottom for UMC’s Opportunities and locate appropriate document in the list of current solicitations.

RFI responses will be accepted at the University Medical Center address specified above on, or before, **August 22nd, 2011** at 2:00 p.m., based on the time clock at the UMC Contracts Management office. Proposals are time-stamped upon receipt.

PUBLISHED:
Las Vegas Review Journal
August 7, 2011

I. Introduction

1. University Medical Center of Southern Nevada (UMC), located in Las Vegas, Nevada, is a county-owned, acute-care hospital, organized under Nevada Revised Statute Chapter 450, with over 500 beds, a Level 1 Trauma Center, a Level 2 Pediatric Trauma Center and 10 urgent care clinics.
2. UMC has a requirement for Molecular Testing Equipment. At this time, UMC is conducting a market analysis to gain insight on the Molecular Testing community. Some of the information UMC is looking for is; types of equipment on the market and the test menu available (FDA approved, ASR, non-FDA approved), what tests are in development, the size of the equipment along with the placement requirements, and what types of purchases/leases/reagent rental programs are available.
3. UMC would like each Respondent to provide information on their products by completing the attached spreadsheets and to provide information on the types of molecular testing equipment and the types of tests each one can perform.

II. RFI Process and Evaluation

1. This RFI is being released by University Medical Center of Southern Nevada to assist us with market analysis to determine the capabilities of molecular testing equipment in the market, the test menu available (FDA approved, ASR, non-FDA approved), tests in development, size and placement requirements, and what types of purchases/leases/reagent rental programs are available. UMC will analyze the responses to this RFI to determine the most advantageous procurement method and determining the best way forward for UMC.

a. Terms

The term "Owner" or "UMC", as used throughout this document, will mean the University Medical Center of Southern Nevada

The term "BCC", as used throughout this document, will mean the Board of Hospital Trustees or the Board of County Commissioners, which is the governing body of Clark County and UMC

The term "County", as used throughout this document, will mean Clark County, Nevada, the owner of UMC.

The term "Respondent", as used throughout this document, will mean a respondent to this Request for Information.

The term "RFI", as used throughout this document, will mean Request for Information.

The term "RFP", as used throughout this document, will mean Request for Proposal.

b. Dates and Schedule

Key Event	Date/Range
RFI Publication Date	August 7, 2011
Deadline for Submitting RFI Responses	August 22, 2011
Response reviews and way forward determination	September 2011

c. Evaluation Process

1. A team of UMC business and technical representatives will evaluate all RFI responses. This team will be responsible for reviewing the responses and providing direction for UMC's next step.
2. Responses will be evaluated as to their compliance to the following criteria:
 - i. Timely, accurate, and thorough responses to the RFI.
 - ii. Ability to meet the requirements described in the RFI.
 - iii. Proven success of molecular testing equipment in the field.

d. Designated Contact

During the RFI response period, all questions or communication relating to the RFI must be directed to:

Rob Maher, Sr. Management Analyst
1800 West Charleston Boulevard
Las Vegas, NV 89102
Telephone: (702) 207-8846
E-Mail: robert.maher@umcsn.com

e. RFI Submittal Requirements

1. All responses shall be on 8-1/2" x 11" paper. The ideal proposal will be 3-hole punched and bound with a binder clip. Binders or spiral binding is not preferred or required.
2. **RESPONDENT shall submit one (1) paper copy, clearly labeled original and one (1) copy in electronic format of their response.** The electronic media shall be in the form of a CD that contains the entire response in .PDF or Word format. The name of RESPONDENT's firm shall be indicated on the cover of each proposal.
3. All responses must be submitted in a sealed envelope plainly marked with the name and address of the Respondent and the RFI number and title. No responsibility will attach to the Owner or any official or employee thereof, for the pre-opening of, post-opening of, or the failure to open a proposal not properly addressed and identified. **FAXED OR EMAILED RESPONSES ARE NOT ALLOWED AND WILL NOT BE CONSIDERED.**

4. The following are detailed delivery/ mailing instructions for responses:

<u>Hand Delivery</u>	<u>U.S. Mail Delivery</u>	<u>Express Delivery</u>
University Medical Center Contracts Management Trauma Center Building 800 Rose Street, Suite 408 Las Vegas, Nevada 89102	University Medical Center Contracts Management 1800 West Charleston Blvd Las Vegas, Nevada 89102	University Medical Center Contracts Management 800 Rose Street, Suite 408 Las Vegas, Nevada 89102

Regardless of the method used for delivery, Respondent(S) shall be wholly responsible for the timely delivery of submitted responses.

f. Disclaimer

1. This RFI is issued solely for information and planning purposes and does not constitute solicitation. Responses to this notice are not offers and cannot be accepted to form a binding contract. Respondents are solely responsible for all expenses associated with responding to this RFI. Responses shall not contain any confidential information. Any responses marked "confidential" will be rejected. Responses to this RFI will not be returned. Respondents will not be notified of the results of the evaluation and rankings conducted by UMC.

g. Evaluation Information

1. UMC will be evaluating based on the information presented in Respondents' responses. Areas of evaluation, required areas of response, and preferred organization of response are as follows:

a. Executive Summary

- i. This section of the response shall serve to provide Owner with the key elements and unique features of the Respondent by briefly describing their plan to accomplish the project. The Executive Summary should include a projected schedule of major milestones.
- ii. The Executive Summary should also include a list of high-risk areas which may cause concern in completing this project once solicited. Respondent will not be evaluated on this paragraph and cannot lose evaluation points for listing areas of concern.

b. Company Information

- i. Within their response, Respondents should provide a brief overview and history of the company, including contact(s) and contact(s) information for this RFI.

c. Respondent's Experience

Include a brief resume of all similar projects Respondent's firm has performed in the past 3 years. Each project listed shall include the project start and completion dates along with the name, telephone number, and e-mail address of a contact person for the project, for review purposes. All firms are encouraged to indicate their experience of performing related work within the state of Nevada.

d. Required Information

- i. Provide a description of the types of molecular testing equipment available.
- ii. Describe new developments as it relates to testing equipment within this field.
- iii. Provide information on lead times, shipping, installation and implementation.
- iv. Provide a budgetary estimate for each type of solutions. Break out equipment, training, shipping, and installation/implementation.
- v. Provide details on the types of purchase/lease/reagent rental programs available.
- vi. Provide size and operating specifications for each proposed piece of equipment.
- vii. Provide information regarding maintenance contracts for each proposed piece of equipment.
- viii. Provide information regarding interface solutions to Cerner Millineum Laboratory Information System.
- ix. Provide information relating to the analysis mode of each proposed piece of equipment (i.e. random or batch analysis). If both modes apply, separate under what circumstances, or test(s) the analyzer can be run in what mode.
- x. Provide the total technical time required for each assay. Include set-up, extraction and instrument run time.
- xi. Indicate if additional equipment is required to run the equipment not included in the financial information submitted.
- xii. Indicate if any royalties would be paid by UMC for each test. Include the test name and amount of royalty to be paid per test.
- xiii. Provide a timeline for availability relating to the test assays that are in development (i.e. non-FDA approved).

III. Project Scope

1.0 Objective: The objective of this contract is to procure, either by purchase, reagent rental or lease, molecular testing equipment that can perform tests listed in the following spreadsheets.

2.0 Requirements

2.1 Requirement Overview: UMC has a requirement to provide molecular testing to the medical staff. In order to best meet the staff's needs, UMC is in need of new molecular testing equipment that is capable of performing the tests listed below.

2.2 The contractor will be responsible for the delivery, installation, implementation, training, and maintenance of the equipment. Following is a list of services to provide:

- 2.2.1 Delivery: 1800 W. Charleston Blvd., Las Vegas, NV 89102
- 2.2.2 Installation: Provide all tools, equipment and material necessary for proper installation of equipment.
- 2.2.3 Implementation: Provide all necessary operations checks, staff training, and any other requirements to ensure operational compliance.
- 2.2.4 Maintenance: Provide warranty and on-call support and maintenance during the duration of the contract.

3.0 Regulations and Policies

3.1 The equipment shall adhere to all federal, state and local regulations and policies.

4.0 Tests

Adenovirus 3' Hexon	Enterovirus	JC Virus
Adenovirus 5' Hexon	EV	<i>M. pneumoniae</i>
<i>B. parapertussis</i>	Flu A	MRSA
<i>B. pertussis</i>	Flu B	MRSA/SA
BKV	GBS	Norovirus
Borrelia	Group A Strep	Parvovirus
BRAF	HBV	RSV
<i>C. difficile</i>	HCV	RSV Type A
<i>C. pneumoniae</i>	HHV-6	RSV Type B
CDIFF	HIV	<i>T. gondii</i>
CMV	HPV	VZV
CT/NG	HSV-1	
EBV	HSV-2	

IV. Spreadsheets

1.0 Molecular Testing (FDA / ASR/Non-FDA Approved) Additional space is provided to add tests not listed on the spreadsheet.

Molecular Testing RFI

Please complete the following grid for each molecular testing platform available from the company you represent. If the company you represent has more than 1 platform available, use the additional columns to add the names of each platform. Mark an X in the box for each assay available on each testing platform that is FDA approved or sold as an "ASR" (List additional tests if available)

TESTS							
Adenovirus 3' Hexon							
Adenovirus 5' Hexon							
<i>B. parapertussis</i>							
<i>B. pertussis</i>							
BKV							
Borrelia							
BRAF							
<i>C. difficile</i>							
<i>C. pneumoniae</i>							
CDIFF							
CMV							
CT/NG							
EBV							
Enterovirus							
EV							
Flu A							
Flu B							
GBS							
Group A Strep							
HBV							
HCV							
HHV-6							
HIV							
HPV							
HSV-1							
HSV-2							
Influenza A							
Influenza B							
JC Virus							
<i>M. pneumoniae</i>							
MRSA							
MRSA/SA							
Norovirus							
Parvovirus							
RSV							
RSV Type A							
RSV Type B							
<i>T. gondii</i>							
VZV							

Molecular Testing RFI

Please complete the following grid for each molecular testing platform available from the company you represent. If the company you represent has more than 1 platform available, use the additional columns to add the names of each platform. Mark an X in the box for each assay available on each testing platform that is not FDA approved, or in development. (List additional tests if available)

TESTS							
Adenovirus 3' Hexon							
Adenovirus 5' Hexon							
<i>B. parapertussis</i>							
<i>B. pertussis</i>							
BKV							
Borrelia							
BRAF							
<i>C. difficile</i>							
<i>C. pneumoniae</i>							
CDIFF							
CMV							
CT/NG							
EBV							
Enterovirus							
EV							
Flu A							
Flu B							
GBS							
Group A Strep							
HBV							
HCV							
HHV-6							
HIV							
HPV							
HSV-1							
HSV-2							
Influenza A							
Influenza B							
JC Virus							
<i>M. pneumoniae</i>							
MRSA							
MRSA/SA							
Norovirus							
Parvovirus							
RSV							
RSV Type A							
RSV Type B							
<i>T. gondii</i>							
VZV							